A Regulatory Drama
Phenomix: How Everything Right Can Go So Wrong
By Arlene Weintraub
In October 2008, Phenomix Corp. seemed to be on top of the biotech world. After raising $165 million in venture capital to develop its Type II diabetes compound, dutogliptin, the San Diego start-up scored a development deal with Forest Laboratories Inc. potentially worth $340 million.